Setia Vishwas 4

What Happened

• Setia Vishwas, Chief Financial Officer of MapLight Therapeutics (MPLT), was granted a total of 39,125 securities on 2026-02-05: 7,730 shares reported as acquired at $0 and 31,395 derivative awards (RSUs) reported at $0. The transactions are listed as awards/grants (code A) on the Form 4.
• The RSUs are contingent rights to receive common stock upon vesting (see footnotes); the filing reports no cash paid for these awards.

Key Details

• Transaction date: 2026-02-05; Form 4 filed 2026-02-09 (within the typical two-business-day filing window).
• Reported prices/values: both grants reported at $0 (common for restricted stock/RSU compensation).
• Vesting for RSUs (per footnote F1/F2): 1/4 of the RSUs vest on January 1, 2027, then 1/16 of the RSUs vest on each subsequent April 1, July 1, October 1 and January 1 thereafter; each RSU converts to one share on vesting.
• The filing includes an additional footnote (F3) describing an option-vesting schedule (1/4 vesting one year after grant and then monthly thereafter); no option exercise or option grant transaction is reported in this Form 4.
• The filing does not state a post-transaction total of shares beneficially owned in the data provided here.

Context

• These are compensation awards (not open-market purchases or sales). Awards/RSUs are commonly used for employee compensation and vest over time; they do not by themselves indicate an immediate buy/sell decision by the insider.
• RSUs are derivative awards — the holder receives actual shares only as they vest (per the schedule above).